Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bath & Body Works Inc (BBWI) vs McKesson Corporation (MCK) Price & Performance

Bath & Body Works IncTrade
McKesson CorporationTrade

Price performance (Past 24H)

Key statistics

Bath & Body Works Inc vs McKesson Corporation — how do they compare? Bath & Body Works Inc trades at $18.9 (market cap $3.89B), while McKesson Corporation trades at $899.06 (market cap $102.58B). The key difference: McKesson Corporation is far larger — about 26.4× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays the higher dividend (4.14%). Which is the better fit depends on your goals.

BBWIMCK
Market Cap
$3.89B$102.58B
Sector
Consumer CyclicalHealth
52-Week High
$31.87$995.69
52-Week Low
$14.85$659.01
Enterprise Value
$7.79B$109.12B
Dividend Yield
4.14%0.43%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bath & Body Works Inc

BBWI trades at $20.36, up 1.09% daily, with a bearish technical signal but strong fundamentals including a low P/E of 5.78 and net income margin of 10.03%. Recent earnings show mixed beats, while cash flow trends improved in 2026 forecasts. The company expands globally via Ulta Beauty partnerships and Brazil entry, supporting growth narratives amid revenue declines from $7.9B in 2022 to $7.3B in 2025.

Outlook balances deep value with execution risks; analyst consensus price target of $22.11 implies upside, but high debt and revenue pressures require monitoring turnaround initiatives. Opportunities lie in margin strength and expansion, while risks include competitive retail headwinds and liability management.

McKesson Corporation

McKesson (MCK) trades at $869.58, down 0.14% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with revenue growth to $359.05B in 2025 and consistent earnings beats, including Q2 2026 EPS of $9.93 versus $9.56 expected. Valuation metrics like P/E of 23.33 and P/S of 0.26 indicate reasonable pricing relative to peers. Recent news highlights Q1 2027 results exceeding expectations and raised full-year guidance, driven by specialty drug and oncology growth.

Outlook remains positive with 80% analyst buy ratings and a $1,000 consensus price target, suggesting 15% upside. Risks include thin net margins of 1.12% and high liabilities at $76.83B, which could pressure equity during economic downturns. Investors should focus on execution of raised guidance and margin improvements from cost efficiencies.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bath & Body Works Inc

Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.

Read more on BBWI

About McKesson Corporation

McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.

Read more on MCK